Investor Service Announcement no. 4/2008 Hørsholm, Denmark, August 18, 2008 LifeCycle Pharma A/S to Host Conference Call Announcing Interim Results for the First Half of the Year 2008 LifeCycle Pharma A/S (OMX: LCP) will announce interim results for the first half of the year of 2008 (January 1 - June 30) on Thursday, August 21, 2008. The results will be announc- d before the opening of OMX Nordic Exchange Copenhagen, the Danish financial market. The Executive Management of the company will host an accompanying conference call to discuss the financial results on Thursday, August 21, 2008, at 15:00 CET (Denmark); 14:00 GMT (London); 09:00 A.M. ET (New York); 06:00 A.M. PT (San Francisco). To access the live conference call, please dial one of the following numbers: +1 866 966 5335 (US) +44 2030 032 666 (UK) +45 8088 8649 (DK) An audio replay of the conference call will be available on www.lcpharma.com fr- m Friday, August 22, 2008, at 16:00 CET (Denmark); 15:00 GMT (London); 10:00 A.M. ET (New York); 07:00 A.M. PT (San Francisco), through Monday, September 22, 2008, by dialing +44 2081 961 998 (UK) or +1 866 583 1035 (US), and entering access code 8403 264#. For more information, please contact: Hans Christian Teisen Executive Vice President and Chief Financial Officer +45 7033 3300 HCT@lcpharma.com page 1 of 2 Investor Service Announcement no. 4/2008 About LifeCycle Pharma A/S (“LCP”) LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering TM product, Fenoglide , currently on the US market and a diversified near‐ and medium‐term pipeline, including four product candidates in clinical trials and two in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com. page 2 of 2 Investor Service Announcement no. 4/2008
LifeCycle Pharma A/S to Host Conference Call Announcing Interim Results for the First Half of the Year 2008
| Source: Veloxis Pharmaceuticals A/S